338 related articles for article (PubMed ID: 12107919)
1. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
4. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
5. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
7. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Testro AG; Angus PW
J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
[No Abstract] [Full Text] [Related]
8. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
Kalambokis GN; Tsianos EV
Hepatology; 2008 Aug; 48(2):686. PubMed ID: 18666233
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
[TBL] [Abstract][Full Text] [Related]
11. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
Arroyo V; Terra C; Ginès P
J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
[No Abstract] [Full Text] [Related]
12. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
13. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.
Schmidt LE; Ring-Larsen H
Curr Pharm Des; 2006; 12(35):4637-47. PubMed ID: 17168767
[TBL] [Abstract][Full Text] [Related]
14. Review article: pharmacological treatment of hepatorenal syndrome.
Ginès P; Torre A; Terra C; Guevara M
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
[TBL] [Abstract][Full Text] [Related]
15. [Physiopathology of refractory ascites and the hepatorenal syndrome].
Arroyo V
Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
[No Abstract] [Full Text] [Related]
16. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
17. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Rice JP; Skagen C; Said A
Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
[TBL] [Abstract][Full Text] [Related]
18. [Hepatorenal syndrome: a new therapeutic approach?].
Gerbes AL; Gülberg V
Z Gastroenterol; 1999 Sep; 37(9):983-5. PubMed ID: 10522370
[No Abstract] [Full Text] [Related]
19. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
20. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
